What is Ziconotide?
Ziconotide is a venom-derived peptide medicine that blocks N-type calcium channels. Its pain research concerns specialist intrathecal delivery, not a generic injectable recovery peptide.
Biological role or research focus
Specialist intrathecal pain treatment.
The study was short and examined a specialized delivery route in a severely affected population. It cannot establish long-term benefit-risk or a general injury-recovery use.
Role reference: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. · 2004 ↗
Names you may encounter
Prialt
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Venom-derived N-type calcium-channel blocker peptide
- Research focus
- Specialist intrathecal pain treatment
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Quick answers
- Is Ziconotide FDA approved?
- Yes. Prialt intrathecal infusion (NDA 021060, approved December 2004) for severe chronic pain. Source ↗
- Is Ziconotide safe?
- Ziconotide is a non-opioid drug for severe chronic pain, given only by specialists; its boxed warning covers serious psychiatric and neurological effects, and confusion, dizziness and nausea are common. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Ziconotide banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Ziconotide refractory-pain randomized trial (2004) | Human randomized trial | 111 patients with refractory pain due to cancer or AIDS, studied at 32 centers. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2004
Ziconotide refractory-pain randomized trial
Did intrathecal ziconotide reduce refractory pain versus placebo?
- Population / model
- 111 patients with refractory pain due to cancer or AIDS, studied at 32 centers.
- Study design
- Randomized double-blind placebo-controlled intrathecal study with a short titration period and a five-day maintenance phase.
- Main finding
- Mean visual-analog pain-intensity improvement was 53.1% with ziconotide versus 18.1% with placebo.
- Limits & context
- The study was short and examined a specialized delivery route in a severely affected population. It cannot establish long-term benefit-risk or a general injury-recovery use.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
13 registered studies name Ziconotide as an intervention; 2 are recruiting or under way, 1 has not started recruiting yet, 7 completed and 3 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 13 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
The Diagnosis and Treatment of Neuropathic Pain. ↗
Deutsches Arzteblatt international · 2024 Dec 13 · Journal Article, Review
Read available full text ↗
Ziconotide. ↗
· 2006 · Review
The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. ↗
Pharmacological reviews · 2015 Oct · Journal Article, Research Support, Non-U.S. Gov't, Review
Read available full text ↗
Ziconotide. ↗
· 2025 Jan · Study Guide
Risks & interactions
Ziconotide is a non-opioid drug for severe chronic pain, given only by specialists; its boxed warning covers serious psychiatric and neurological effects, and confusion, dizziness and nausea are common.
Severe psychiatric symptoms and neurological impairment can occur. It must not be used in people with a history of psychosis, and patients need close watching for confusion, hallucinations, and changes in mood or alertness.
Safety is established by FDA labeling from trials in more than a thousand adults with severe chronic pain. Confusion is more common in older adults.
Take extra care with: Blood thinners or bleeding problems
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- History of psychosis
- Allergy to ziconotide or any ingredient
- Conditions that make spinal-canal drug delivery unsafe, such as infection at the site, uncontrolled bleeding or spinal canal blockage
Interactions
- Opioids delivered into the spinal canal: combination not recommended
- Sedatives, antiepileptics, neuroleptics or diuretics: higher risk of reduced consciousness
- Other drugs that depress the nervous system: more dizziness and confusion
Serious risks
- Hallucinations, paranoia, psychosis and other psychiatric reactions
- Depression with risk of suicide
- Memory and thinking problems, reduced alertness or unresponsiveness
- Meningitis and other infections
- Raised creatine kinase (a muscle enzyme)
Common side effects
- dizziness
- nausea
- confusion
- abnormal eye movements (nystagmus)
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Prialt (ziconotide) prescribing information ↗
What the featured evidence can tell us
The complete product information is needed for neurological and other precautions. Intrathecal medicine requires specialist selection, delivery, and monitoring; the trial is not an instruction for self-administration.
Source: EMA · Prialt overview ↗
Identity, route, and evidence limits
The study was short and examined a specialized delivery route in a severely affected population. It cannot establish long-term benefit-risk or a general injury-recovery use.
Official product context · checked October 4, 2026
EMA describes confusion, memory impairment, dizziness, and other neurological effects among reported adverse reactions. Specialist delivery and the full product precautions are essential to interpreting its benefits.
Source: EMA · Prialt authorization and product overview ↗
Regulatory status
- U.S. FDA approval
- Approved
Prialt intrathecal infusion (NDA 021060, approved December 2004) for severe chronic pain. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Medicine status & clinical context
EMA describes Prialt as an authorized medicine for severe chronic pain requiring intrathecal analgesia. This is a specialist pain-treatment context; an authorization for a particular medicine is not approval of a supplier’s preparation.
The selected trial studied refractory pain in patients with cancer or AIDS. EMA’s Prialt information provides the product context; specialist administration and product-specific precautions matter.
Source: EMA · Prialt authorization and product overview ↗
Source: EMA · Prialt overview ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
How Ziconotide works
Blocking N-type calcium channels modifies pain-signal transmission. The route is part of the intervention: delivery into spinal fluid is different from a skin or muscle injection.
Molecular structure
Questions worth asking
- Does this establish a general-purpose pain peptide?
- What population, comparator, and route were actually studied?
- The study was short and examined a specialized delivery route in a severely affected population. It cannot establish long-term benefit-risk or a general injury-recovery use.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Does this establish a general-purpose pain peptide?
No. The trial concerns a particular medicine, intrathecal route, and refractory-pain population. Those findings cannot be transferred to an unrelated preparation or route.
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Does the official medicine reference cover every use discussed online?
No. The reference covers defined products and clinical settings. Research outside those uses needs separate evidence and does not extend the medicine’s authorization.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.